Breaking News, Promotions & Moves

Blend Therapeutics Appoints CSO

Wooster brings extensive oncology experience

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Richard Wooster, Ph.D., has been appointed chief scientific officer at Blend Therapeutics. Dr. Wooster will be responsible for leading the company’s R&D strategy and clinical operations for lead drug candidates focused on oncology.   Prior to joining the company, Dr. Wooster was vice president and head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline, where he led the evaluation of the metabolic pathways that are deregulated in cancer. He previously led the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters